Biodesign of a renal-protective peptide based on alternative splicing of B-type natriuretic peptide

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 27, 2009, Pages 11282-11287

  Pan, Shuchong ^a   Chen, Horng H ^a   Dickey, Deborah M ^b   Boerrigter, Guido ^a   Lee, Candace ^a   Kleppe, Laurel S ^a   Hall, Jennifer L ^b   Lerman, Amir ^a   Redfield, Margaret M ^a   Potter, Lincoln R ^b   Burnett Jr , John C ^a   Simari, Robert D ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Kidney; Myocardial; Vasoactive

Indexed keywords

AMINO ACID; ANGIOTENSIN; ANTISERUM; BRAIN NATRIURETIC PEPTIDE; CYCLIC GMP; NATRIURETIC PEPTIDE RECEPTOR A; NATRIURETIC PEPTIDE RECEPTOR B; RENIN;

ALTERNATIVE RNA SPLICING; AMINO ACID SEQUENCE; ANGIOTENSIN BLOOD LEVEL; ANIMAL EXPERIMENT; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DIURESIS; DOG; DRUG DESIGN; DRUG DOSE ESCALATION; EMBRYO; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART PACING; HEART WORK; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IMMUNOREACTIVITY; IN VIVO STUDY; INTRON; MEAN ARTERIAL PRESSURE; MESANGIUM CELL; NATRIURESIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PEPTIDE SYNTHESIS; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN STRUCTURE; RENAL PROTECTION;

ALTERNATIVE SPLICING; AMINO ACID SEQUENCE; ANIMALS; CATTLE; DOGS; DRUG DESIGN; HEART FAILURE; HUMANS; KIDNEY; MOLECULAR SEQUENCE DATA; NATRIURETIC PEPTIDE, BRAIN; PEPTIDES; RECEPTORS, ATRIAL NATRIURETIC FACTOR; RNA, MESSENGER;

EID: 67650469513     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0811851106     Document Type: Article

References (19)

1. Matlin AJ, Clark F, Smith CW (2005) Understanding alternative splicing: Towards a cellular code. Nat Rev Mol Cell Biol 6:386-398.
2. Blencowe BJ (2006) Alternative splicing: New insights from global analyses. Cell 126:37-47.
3. Sudoh T, Kangawa K, Minamino N, Matsuo H (1988) A new natriuretic peptide in porcine brain. Nature 332:78-81.
4. Mukoyama M, et al. (1991) Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide, and brain natriuretic peptide. J Clin Invest 87:1402-1412.
5. Yan W, Wu F, Morser J, Wu Q (2000) Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme. Proc Natl Acad Sci USA 97:8525-8529.
6. Garbers DL, et al. (2006) Membrane guanylyl cyclase receptors: An update. Trends Endocrinol Metab 17:251-258.
7. Publication Committee for the VMAC Investigators (2002) Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: A randomized controlled trial. J Am Med Assoc 287:1531-1540.
8. Sackner-Bernstein JD, Skopicki HA, Aaronson KD (2005) Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 111:1487-1491.
9. Dickey DM, Burnett JC, Jr., Potter LR (2008) Novel bifunctional natriuretic peptides as potential therapeutics. J Biol Chem 283:35003-35009.
10. Chen HH, Huntley BK, Schirger JA, Cataliotti A, Burnett JC, Jr (2006) Maximizing the renal cyclic 3′-5′-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: A novel strategy to improve renal function in experimental overt heart failure. J Am Soc Nephrol 17:2742-2747.
11. Ben-Dov C, Hartmann B, Lundgren J, Valcarcel J (2008) Genome-wide analysis of alternative pre-mRNA splicing. J Biol Chem 283:1229-1233.
12. Takahashi T, Allen PD, Izumo S (1992) Expression of A-, B-, and C-type natriuretic peptide genes in failing and developing human ventricles. Correlation with expression of the Ca(2+)-ATPase gene. Circ Res 71:9-17.
13. Rutherford RA, Matsuda Y, Wilkins MR, Polak JM, Wharton J (1994) Identification of renal natriuretic peptide receptor subpopulations by use of the non-peptide antagonist, HS-142-1. Br J Pharmacol 113:931-939.
14. Hall JL, et al. (2004) Genomic profiling of the human heart before and after mechanical support with a ventricular assist device reveals alterations in vascular signaling networks. Physiol Genomics 17:283-291.
15. Steiner AL, Parker CW, Kipnis DM (1972) Radioimmunoassay for cyclic nucleotides. I. Preparation of antibodies and iodinated cyclic nucleotides. J Biol Chem 247:1106-1113.
16. Supaporn T, et al. (1996) Blunted cGMP response to agonists and enhanced glomerular cyclic 3′,5′-nucleotide phosphodiesterase activities in experimental congestive heart failure. Kidney Int 50:1718-1725.
17. Chaumet-Riffaud P, Oudinet JP, Sraer J, Lajotte C, Ardaillou R (1981) Altered PGE2 and PGF2 alpha production by glomeruli and papilla of sodium-depleted and sodium-loaded rats. Am J Physiol 241:F517-524.
18. Hasdai D, Mathew V, Schwartz RS, Holmes DR, Jr, Lerman A (1997) The effect of basic fibroblast growth factor on coronary vascular tone in experimental hypercholesterolemia in vivo and in vitro. Coron Artery Dis 8:299-304.
19. Hasdai D, et al. (1998) Insulin and insulin-like growth factor-I cause coronary vasorelaxation in vitro. Hypertension 32:228-234.